Pharma — India Patent Cases
967 decisions indexed
Page 22 of 33 · 967 total
Eli Lilly And Company v.Bryan Pharmaceuticals Through Its Proprietor Mr. Laxmi Kand Pal / Navneet Kand Pal & Ors.
The suit sought permanent injunction against defendants for infringing Indian Patent No. 270765 concerning Baricitinib (Barinat). The patent holder alleged that licensed companies were marketing and exporting the product outside its approved use (COVID-19) for Rheumatoid Arthritis, primarily through e-commerce platforms like Indiamart.
Novartis Ag v.Windlas Biotech Pvt Ltd
Novartis initiated multiple suits against various defendants, including Windlas Biotech and Eris Lifesciences, alleging infringement of Indian Patent No. IN229051, which covers a combination drug (Valsartan + Sacubitril) used to treat cardiovascular disease. The Delhi High Court addressed applications seeking interim injunctions and access to distribution details. While the court maintained an interim injunction against manufacturing and selling the patented composition, it also directed Eris Lifesciences Limited to deposit Rs. 5 crores due to the marketing of stock post-infringement.
Bristol Myers Squibb Holdings Ireland Unlimited Company v.Jigs Chemical Limited & Anr.
The Plaintiff filed a suit seeking an injunction against Defendant No.1, alleging that the defendant was advertising and selling 'APIXABAN' (a patented pharmaceutical preparation) as an Active Pharmaceutical Ingredient (API). The court found a prima facie case for infringement and granted an ex parte ad interim injunction restraining the manufacturing and sale of APIXABAN.
Vifor International Ltd. v.Dr Reddy's Laboratories Limited
The plaintiffs claim infringement of their patent related to drugs comprising 'FERRIC CARBOXYMALTOSE'. The defendant argues that MSN Laboratories is the manufacturer for them.
Merck Sharp And Dohme Corp v.Actis Generics Pvt Ltd
The suit involved a dispute over Indian Patent No. 209816, which covers Sitagliptin for diabetes treatment. The parties amicably resolved their disputes through a settlement agreement dated March 15, 2022.
Bristol Myers Squibb Holdings Ireland Unlimited Company v.Angle Bio Pharma
The Plaintiffs filed a suit seeking an injunction against Defendant No.1 for infringing their patented pharmaceutical preparation 'APIXABAN'. The Plaintiffs alleged that Defendant No.1 was advertising and selling the product through various platforms including Indiamart and Tradeindia. The Court granted an ex parte ad interim injunction restraining Angle Bio Pharma from manufacturing or selling APIXABAN without authorization, and directed the intermediary websites to take down the listings.
Micro Labs Limited v.The Controller Of Patents & Anr
The case involves a revocation petition filed by Micro Labs Limited against the patent granted to Bristol-Myers Squibb for a pharmaceutical compound used as an anticoagulant. The court granted an interim injunction restraining Micro Labs from manufacturing and selling the product covered by the patent.
PNB Vesper Life Science Pvt. Ltd v.The Controller General of Patents, Designs & Trademarks
PNB Vesper Life Science Pvt. Ltd challenged the Controller General of Patents' order that deemed its patent application, relating to novel Cholecystokini Receptor Ligands, as abandoned. The petitioner argued that the abandonment was based on procedural failures and clerical errors by agents, not due to lack of interest in the invention. The Madras High Court acknowledged the violation of timelines but emphasized principles of natural justice, ultimately restoring the application for fresh consideration.
Boehringer Ingelheim International GmbH v.Dr. Reddy's Laboratories Limited
Plaintiffs (Boehringer Ingelheim) filed a suit seeking permanent prohibitory injunction against the defendants (Dr. Reddy's Laboratories) for infringing their patent No. 268846, covering Empagliflozin products. The court heard applications concerning the continuation and vacation of an existing ad-interim injunction.
Vifor International Ltd v.Unijules Life Sciences Limited
The dispute involved allegations of infringement regarding Ferric Carboxymaltose protected under Indian Patent No. 221536. The parties referred the matter to mediation, resulting in a Settlement Agreement dated 21.02.2022.
Boehringer Ingelheim International GmbH v.Msn Laboratories Private Limited
The plaintiffs (Boehringer Ingelheim) sought confirmation of an interim injunction restraining the defendants (Msn Laboratories) from infringing their patent (IN 268846) related to Empagliflozin. The court addressed two main issues: the merits of the injunction and whether the defendant could challenge it without a written statement, ultimately allowing the defendant's application for vacation.
Sun Pharmaceutical Industries Ltd v.Daxia Healthcare & Ors.
In a trademark infringement suit concerning the product SILODAX-8 D, the Delhi High Court directed both parties toward mediation. The defendants agreed not to manufacture or sell further stock of the infringing product while also committing to provide details of all products manufactured and sold to date. This order signals a judicial preference for alternative dispute resolution in complex IP disputes.
Eris Lifesciences Limited v.Controller Of Patents & Anr.
Eris Lifesciences Limited filed a revocation petition challenging Patent No. IN 243301, arguing that it should be revoked because the claims were covered by an earlier genus patent (IN 227719). The Delhi High Court noted that another appeal concerning the same patent was already pending before the court. Consequently, the court directed both parties to serve notices upon each other and listed the matter together with the existing appeal for a hearing on April 6, 2022.
Precise Bio Pharma Pvt Ltd v.Assistant Controller Of Patents And Designs & Anr.
Precise Bio Pharma Pvt Ltd challenged an order by the Assistant Controller of Patents which dismissed a pre-grant opposition against its patent application. The Petitioner argued that the impugned order was not a 'speaking order' and lacked sufficient reasoning. The High Court agreed, setting aside the order and remanding the matter for a reasoned decision.
GLAXO GROUP LIMITED AND OTHERS v.RAJIV MUKUL AND ANR.
This Delhi High Court order addresses an execution petition filed by Glaxo Group Limited seeking enforcement of a prior decree. The core issue is the alleged infringement and passing off committed by the judgment debtors who began selling products under the deceptively similar trade name 'BETNEVIN'. Although the original suit covered various trademarks, the petitioners argued that their rights in 'BETNOVATE' and 'BETNESOL' were encompassed within the general scope of the decree. The Court directed notice to the defendants regarding this new alleged infringement, setting the stage for further litigation.
Boehinder Pharma v.Macleods Pharma
Boehinder Pharma filed an application seeking ad-interim relief to restrain Macleods Pharma from infringing its patent rights over 'Linagliptin'. The applicants argued that their patent was still valid and the respondent was manufacturing and selling the product under brands LINAMAC and LINAONE. The court, finding a prima facie case, granted an interim injunction restraining the respondent from manufacturing or selling Linagliptin.
Merck Sharp And Dohme Corp. v.Beaukev Pharma International Pvt. Ltd.
The plaintiffs filed a suit alleging infringement of their patent (IN 209816) concerning Sitagliptin. The court closed the defendant's right to file a written statement and passed an interim injunction restraining the defendant from manufacturing or selling the patented drug until the final disposal of the suit.
Novartis Ag v.Windlas Biotech Pvt. Ltd.
The cases involve Novartis AG against Windlas Biotech Pvt. Ltd. and Eris Lifesciences Limited regarding commercial disputes. The hearings are scheduled for further directions.
PRECISE BIO PHARMA PVT. LTD. v.ASSISTANT CONTROLLER OF PATENTS AND DESIGNS & ANR.
The petitioner filed a petition seeking a stay against an order passed by the Assistant Controller of Patents and Designs. This order rejected the pre-grant opposition filed by Precise Bio Pharma Pvt. Ltd. regarding Indian Patent Application No. 2471/DELNP/2013 under Section 25(1) of the Patents Act, 1970.
Sun Pharma Laboratories Limited v.Walpar Healthcare And Anr.
Sun Pharma Laboratories Limited filed an Interim Application against Walpar Healthcare & Anr. alleging passing off and trademark infringement concerning their respective marks, DUZELA and DIZELA. The court found a case made out for granting ad-interim relief based on the findings of the previous order.
Msn Laboratories Pvt. Ltd v.Novartis Ag
This appeal before the Telangana High Court concerned an infringement suit filed by Novartis Ag against Msn Laboratories Pvt. Ltd regarding patent IN 229051, which covers a specific Valsartan/Sacubitril combination drug. The respondents (Novartis) had secured an interim injunction based on prima facie evidence of infringement due to the appellant's (Msn Labs) manufacturing approval for a similar formulation. The court examined the statutory provisions of the Patents Act and CPC, ultimately dismissing the appeal and upholding the injunction granted in favor of Novartis.
Astrazeneca Ab v.Westcoast Pharmaceutical Works Limited
The plaintiffs, Astrazeneca Ab, filed a suit alleging that the defendant, Westcoast Pharmaceutical Works Limited, was infringing their Indian Patent IN 297581, which covers the anticancer drug Osimertinib (marketed as Tagrisso). The plaintiffs claimed the defendant was soliciting large orders to manufacture and sell the infringing product without authorization.
Astra Zeneca Ab And Anr. v.Natco Pharma Limited
The dispute concerns alleged infringement of Indian Patents IN 205147 and IN 235625 by Natco Pharma Limited regarding the drug Dapnat/Dapagliflozin. The present application sought to release the defendant from a bank guarantee obligation, but the court declined this prayer.
Bristol-Myers Squibb Holdings Ireland v.Metrochem Api Private Limited
The plaintiffs filed a suit for permanent injunction against the defendant for infringing their patent related to the compound APIXABAN. The defendant is accused of manufacturing and selling APIXABAN API without authorization.
Novartis Ag v.Medipol Pharmaceuticals India Pvt Ltd
The plaintiff, Novartis Ag, filed a suit alleging infringement of its patent (IN 233161) concerning the drug Eltrombopag Olamine. The court found a clear prima facie case in favor of the plaintiff, noting that the rights to the patent had been confirmed previously.
Novartis Ag v.Msn Laboratories Pvt Ltd
The plaintiff alleges that the defendant infringed its patent by launching a product containing Eltrombopag Olamine without a license. The court granted an ex parte injunction against the defendant's product 'REBOPAG'.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. v.The Controller of Patents and Designs and Anr.
The appeal was filed challenging the Assistant Controller's order dated August 24, 2021, which rejected Indian Patent Application No. 201817006495. The appellants argued that the rejection based on multiplicity of inventive concepts violated principles of natural justice as no specific objection was raised in the examination report.
Dr.Reddys Laboratories Limited v.Combitic Global Caplet Pvt Ltd
In this Delhi High Court order, Dr.Reddys Laboratories Limited sought time to challenge the validity of a trademark registered by Combitic Global Caplet Pvt Ltd. The court allowed the application and granted an adjournment of three months. This procedural step allows the plaintiff to formally apply for the rectification of the defendant's trademark registration before the IP Division.
Otsuka Pharmaceutical Co Ltd v.The Controller Of Patents
Otsuka Pharmaceutical Co Ltd filed an appeal challenging the Controller of Patents' order rejecting Indian Patent Application No. 8198/DELNP/2013. The appellant argued that the notice of hearing failed to cite all relevant prior arts ('D2' and 'D3') which were used as grounds for rejection.
Syncom Formulations (I) Ltd v.Cratus Pharma Limited
Syncom Formulations (I) Ltd filed a Commercial IP Suit against Cratus Pharma Limited alleging infringement of its registered trade marks ("CRATUS" and "CRATUS LIFE CARE"). The parties subsequently reached an amicable settlement, which was accepted by the court.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.